Management of atrial fibrillation

BMJ (Online)

Volumn 339, Issue 7736, 2009, Pages 40-45

  Lafuente Lafuente, Carmelo ^a   Mahé, Isabelle ^b   Extramiana, Fabrice ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; METOPROLOL; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; VERNAKALANT; WARFARIN; FIBRINOLYTIC AGENT;

ABDOMINAL PAIN; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLOOD TESTIS BARRIER; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CARDIAC PATIENT; CARDIOVERSION; CATHETER ABLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; CORNEA DISEASE; DEPRESSION; DISEASE CLASSIFICATION; DIZZINESS; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; EMBOLISM; EXERCISE TEST; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEART RATE AND RHYTHM; HUMAN; HYPOTENSION; IMPOTENCE; INTOXICATION; LIVER TOXICITY; LUNG TOXICITY; MORBIDITY; MORTALITY; NAUSEA; NEUROTOXICITY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STROKE; TACHYCARDIA; THROMBOEMBOLISM; THYROID DISEASE; TRANSTHORACIC ECHOCARDIOGRAPHY; VISUAL IMPAIRMENT; ARTIFICIAL HEART PACEMAKER; ELECTROCARDIOGRAPHY; HOSPITALIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; PACEMAKER, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WARFARIN;

EID: 84879264620     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b5216     Document Type: Review

References (30)

1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:e257-354.
3. National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation. (Clinical guideline CG36.) 2006. www.nice.org.uk/Guidance/CG36.
4. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000;49(1):47-59.
5. AFFIRM Investigators. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8.
6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
7. Atrial Fibrillation Investigators. Echographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from three clinical trials. Arch Intern Med 1998;158:1316-20.
8. Aspinall SL, DeSanzo BE, Trilli LE, Good CB. Bleeding risk index in an anticoagulation clinic assessment by indication and implications for care. J Gen Intern Med 2005;20:1008-13.
9. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:1269-75.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
11. Singer DE, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GJH, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:S546-92.
12. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;(3):CD006186.
13. BAFTA investigators, Midland Research Practices Network (MidReC); Mant J, Hobbs F, Fletcher K, Roalfe A, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
14. ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
15. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;(4):CD005049.
16. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators; Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation (the AFFIRM STUDY). N Engl J Med 2002;347:1825-33.
17. Atrial Fibrillation and Congestive Heart Failure (AF-CHF) Investigators; Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.
18. De Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-62.
19. Testa L, Biondi-Zoccai GG, Russo AD, Bellocci F, Andreotti F, Crea F. Rate-control vs rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005;26:2000-6.
20. Miller MR, McNamara RL, Segal JB, Kim N, Robinson KA, Goodman SN, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract 2000;49:1033-46.
21. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002;87:535-43.
22. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009;84:234-42.
23. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-91.
24. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000;101:1138-44.
25. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
26. Noheria A, Kumar A, Wylie Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008;168:581-6.
27. Jaïs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505.
28. PABA-CHF Investigators; Khan MN, Jaïs P, Cummings J, di Biase L, Sanders P, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-85.
29. ATHENA Investigators; Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
30. RE-LY Steering Committee and Investigators; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.